ProfileGDS5678 / 1450462_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 36% 37% 37% 36% 45% 38% 35% 37% 37% 37% 37% 38% 37% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8656436
GSM967853U87-EV human glioblastoma xenograft - Control 22.8481637
GSM967854U87-EV human glioblastoma xenograft - Control 32.8436637
GSM967855U87-EV human glioblastoma xenograft - Control 42.7582136
GSM967856U87-EV human glioblastoma xenograft - Control 52.9959245
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9528838
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8404535
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8257137
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.812437
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8368537
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.833237
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.827338
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8393137
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8403137